Last updated on July 2020

A Study of Atezolizumab Plus Nab-Paclitaxel or Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic Triple-Negative Breast Cancer


Brief description of study

Study MO39874 is an open-label, phase IIIb, single arm, multicenter study to evaluate the safety and treatment efficacy of atezolizumab plus nab-paclitaxel/paclitaxel in patients with PD-L1-positive unresectable locally advanced or metastatic triple-negative adenocarcinoma of the breast (TNBC) who have not received prior systemic cytotoxic therapy for unresectable locally advanced or metastatic TNBC.

Clinical Study Identifier: NCT04148911

Find a site near you

Start Over

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Volunteer Sign-up

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.